Evidence map›Paper›PMID 29296824›Full record

ArticleBlood advances2017

Systematic

Elizabeth A Morgan, Mark N Lee, Daniel J DeAngelo, David P Steensma, Richard M Stone, Frank C Kuo, Jon C Aster, Christopher J Gibson, R Coleman Lindsley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Genomics of LGL leukemia and select other rare leukemia/lymphomas.Best practice & research. Clinical haematology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizabeth A MorganDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and.ORCID 0000-0001-5880-9337
Mark N LeeDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
David P SteensmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Frank C KuoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and.
Jon C AsterDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and.
Christopher J GibsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
R Coleman LindsleyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Funding

Determining the Role of BCOR Mutations in Myeloid MalignanciesK08CA204734 · NCI · DANA-FARBER CANCER INST · PI LINDSLEY, ROBERT COLEMAN · 2016 to 2020
$813k
NCI NIH HHS K08 CA204734
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID29296824
PMCPMC5728102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.